LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Listă Acțiuni・Ovid therapeutics Inc

Ovid therapeutics Inc

Închisă

SectorSănătate

2.63 -5.73

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

2.61

Maxim

2.65

Indicatori cheie
By Trading Economics
Venit	22M 9.7M
Vânzări	586K 718K
Marjă de profit	1,345.822
Angajați	23
EBITDA	-152K -12M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+102.66% upside

Dividende
By Dow Jones
Următoarele câștiguri	19 mai 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	344M 483M
Deschiderea anterioară	8.36
Închiderea anterioară	2.63

Sentimentul știrilor

By Acuity

50%

137 / 345 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

0.275 / 0.33 Suport & Rezistență

Ovid therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

15 mai 2026, 22:47 UTC

Acțiuni populare

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 mai 2026, 22:16 UTC

Achiziții, Fuziuni, Preluări

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 mai 2026, 22:00 UTC

Principalele dinamici ale pieței

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 mai 2026, 18:09 UTC

Principalele dinamici ale pieței

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15 mai 2026, 16:02 UTC

Câștiguri

Principalele dinamici ale pieței

Forward Industries Shares Fall on New Debt as Solana Value Drops

15 mai 2026, 14:55 UTC

Principalele dinamici ale pieței

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

16 mai 2026, 16:27 UTC

Achiziții, Fuziuni, Preluări

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 mai 2026, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 mai 2026, 22:17 UTC

Achiziții, Fuziuni, Preluări

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mai 2026, 21:59 UTC

Achiziții, Fuziuni, Preluări

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 mai 2026, 21:50 UTC

Achiziții, Fuziuni, Preluări

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mai 2026, 21:30 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 mai 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 mai 2026, 20:19 UTC

Acțiuni populare

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 mai 2026, 19:41 UTC

Achiziții, Fuziuni, Preluări

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 mai 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 mai 2026, 18:35 UTC

Câștiguri

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15 mai 2026, 17:28 UTC

Market Talk

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15 mai 2026, 16:50 UTC

Achiziții, Fuziuni, Preluări

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15 mai 2026, 16:24 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15 mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

15 mai 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 mai 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 mai 2026, 15:55 UTC

Market Talk

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15 mai 2026, 15:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 mai 2026, 15:20 UTC

Market Talk

Silver Plunges on Inflation Worries -- Market Talk

15 mai 2026, 15:20 UTC

Câștiguri

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

Comparație

Modificare preț

Ovid therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

102.66% sus

Prognoză pe 12 luni

Medie 5.33 USD 102.66%

Maxim 7 USD

Minim 4 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOvid therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

8 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 8 analiști care au acordat evaluări ale acțiunilor Ovid therapeutics Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

0.275 / 0.33Suport & Rezistență

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

137 / 345 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.